title: Converting biology into clinical benefit: lessons learned from BRAF inhibitors.
abstract: The identification and pharmacological targeting of activatingBRAFmutations in melanoma has led to significant improvements in patient outcomes. This perspective paper illustrates the lessons learned from the study ofBRAFmutations and the development of BRAF inhibitors. The relevance of these lessons to the development of future targeted therapies is highlighted.
authors.affiliation: The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA.
authors.forename: Jennifer
authors.initials: J
authors.lastname: McQuade
authors.affiliation: The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA.
authors.forename: Michael A
authors.initials: MA
authors.lastname: Davies
keywords: BRAF; NRAS; PI3K–AKT pathway; melanoma; resistance; targeted therapy